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approach to costing and uptake among populations considered. CONCLUSIONS:
Rx-to-OTC switches are a real opportunity to realise savings for budget holders and
productivity gains for employers. More robust economic models are required to
estimate the impact of the switches in Europe.
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OBJECTIVES: Health policy and funding for medications classed as ‘lifestyle’ have
received considerable scrutiny by public health officials as well as politicians. This
has limited public funding and reimbursement for these products in many Euro-
pean countries. A detailed assessment of the variation in payer coverage polices for
lifestyle medications across Europe was conducted. METHODS: The top ‘lifestyle’
indications and associated medications were identified from a literature search
using WHO, PubMed, and ScienceDirect. Selection criteria for the medications in-
cluded being first-to-market in the identified indication or being referenced as the
only off-label treatment for the specified use. Public reimbursement databases (16)
were used to analyze the health technology assessment and reimbursement deci-
sions across European countries (14) for each lifestyle indication. Reimbursement
was classified as favourable (broad/restricted but accessible) or no coverage (not
funded). Where available, justifications for coverage decisions were analysed to
determine the drivers of positive and negative coverage decisions. RESULTS: Life-
style indications where products have achieved high levels of reimbursement in-
clude Dyspepsia (100%), Delaying Menstruation (91%), Restless Leg Syndrome
(87%), and Alcohol Dependence (85%). Those with the worst coverage are Hair Loss
(0%), Hypoactive Sexual Desire Disorder (0%), Erectile Dysfunction (13%), and
Weight Loss (15%). Of the 14 countries researched, those offering the most favour-
able coverage environments for lifestyle treatments were: Belgium (70%), France
(69%), and Austria (69%). The countries with the most limited (no available) cover-
age for lifestyle drug therapies were The Netherlands (13%) and Sweden (25%). Four
general characteristics are associated with better access to market: Cross-Usage in
Other Indications, Areas with High Societal Costs, Diseases that Affect Family Plan-
ning, and Older Therapy Areas. CONCLUSIONS: With pressure on public health
resources, European payers are resistant to the allocation of funds for medications
with lifestyle indications. Despite this, barriers to reimbursement vary substan-
tially across European markets.
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OBJECTIVES: This study seeks to evaluate the impact of the 2011 German health-
care reform (AMNOG) on the global pricing and reimbursement landscape and its
influence, if any, on global market access strategies. METHODS: Key local regula-
tors were interviewed to understand the scope and mechanism of the mandatory
early benefit assessment as well as its implications in terms of pricing and market
access on a national and global level. Primary research consisted of in-depth phone
interviews with six regulatory stakeholders and industry representatives in Ger-
many. Secondary research was based on data from national and regional health-
care authorities, national statistics offices and IHS Global Insight Healthcare and
Pharmaceutical services. RESULTS: AMNOG has put an end to free pricing in Ger-
many by correlating price to added therapeutic benefit scores and opening the
reference pricing system to all patented medicines. The total transparency of the
early benefit assessment and pricing processes can influence prices not only in
Europe but also worldwide. The availability of results from the Federal Joint Com-
mittee (G-BA)’s benefit assessment can affect the pricing and reimbursement sta-
tus of pharmaceuticals worldwide, while international reference pricing can put
downward pressure on prices in at least 22 other countries. CONCLUSIONS: The
German reform will have an impact beyond the country’s borders. Germany has
traditionally been an early pharmaceutical launch market but the end of free pric-
ing and the prospect of lower price levels for products of no and minor-to-moderate
added value may require a complete reconsideration of the optimal launch se-
quence. While AMNOG has revolutionized the pricing and reimbursement land-
scape in Germany, from a global perspective, the reform is not particularly inno-
vative. Germany’s new pricing process is comparable to the French model whereby
perceived degree of innovation directly impacts medicine prices, and comes near
to the Swiss and Austrian models.
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OBJECTIVES: This analysis compares pricing levels across 15 European countries
and 10 therapy areas in 2010. The differences in the price levels are related to
parallel imports and the innovativeness of prescriptions. METHODS: From IMS
PRICING INSIGHTS pricing information for pharmaceutical products is accessed at
the pack level from 15 countries (EU5-Austria-Ireland-Sweden-Norway-Denmark-
Portugal-Greece-Poland-Hungary-Romania) for 2010. Currency rates are fixed at
2010 levels. For the ten therapy areas, product baskets are constructed for the
comparisons: The therapy areas are defined as Anatomic-Therapeutic-Chemical
(ATC) classes at level 2. The top 100 products by sales in the EU5 in these classes
enter the comparisons. Prices are compared at the manufacturer and the public
sales levels. IMS MIDAS identifies imports related to the products in the baskets.
The innovativeness of products is operationalized as the number of months be-
tween the overall first introduction and the introduction in the countries.
RESULTS: The first result is that international drug price comparisons are ex-
tremely sensitive to methodological issues, e.g. sample selection, exchange rates.
Differences in price build-up structures between countries would dominate cross-
country price differences, if not accounted for. Differences between countries exist
at the ex-manufacturer-level, differences between public sales levels tend to be
larger. Price level differences between countries are not consistent across all ana-
lyzed therapy areas. Higher price levels are related to parallel trade rates across
countries and to an earlier access to new pharmaceutical products.CONCLUSIONS:
The analysis shows price differences across countries related to manufacture pric-
ing and regulation structuring the price build-up and taxes. Higher price levels are
linked to an earlier access to innovative products. Parallel trade flows into coun-
tries with higher price levels, usually from countries with lower price levels, caus-
ing scarcities. Differences in economic development and purchasing powers need
to be analyzed to evaluate these differences in pricing levels.
PHP35
IS VALUE BASED PRICING EXECUTED IN REAL LIFE SITUATION? – GLOBAL
PERSPECTIVES
Mukku S1, Mallinson M2
1Double Helix Consulting Group, London, UK, 2Double Helix Consulting, London, UK
OBJECTIVES: Value assessment of interventions is conducted in some form or the
other, although the importance given to different domains of decisions differ by
markets. The research is aimed to analyse how perspectives on value assessment
of pharmaceuticals or device interventions vary across regions. The research also
analysed how products at launch increase the chances of approval, shorten time to
reimbursement and remain competitive within the value based pricing agenda.
METHODS: The research involved desk research as well interviews with key influ-
encers and decision makers in major markets beyond Europe. More than 25 tele-
phone or face to face interviews with key stakeholders were conducted. RESULTS:
The research indicated that most countries, other than those that use international
price referencing for setting prices use some form of value assessment method
before fixing the reimbursement level and price of the product. The decisions are
predominantly based on level of unmet needs, severity of diseases, level of inno-
vation, clinical differentiation of the new product against its comparators and how
well the product finds it natural place in the treatment pathway. Many forward
regions claim to use value based assessments to set the price of new launches,
most operate within boundaries. In principal value based pricing should not be
fenced with limitations such as cost/QaLY thresholds, budget impact and price-
volume agreements. However in real life these measures are common in markets
all over the world, the main reason being the limitations in health care budgets.
CONCLUSIONS: It is very challenging to reward products based on their intrinsic
value without introducing other hurdles within the current economic environ-
ment. However it also is critical to reward innovation for future investments in
R&D of new drugs. Health care reforms in the future will raise the bar of innovation
and differentiation making it more challenging for the Pharmaceutical industry
and all those involved in developing new medicines.
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OBJECTIVES: EuSANH is a network of science advisory bodies in Europe. The proj-
ect Eusanh-ISA is funded by 7th framework programme of DG Research. It aims to
improve the quality, effectiveness and efficiency of science advice for health across
Europe. Within this project the objective of this work is to learn about the percep-
tions of policy-makers (PM) and science advise bodies’ (SAB) staff concerning the
relationship between these two groups, and the current use of science advice (SA)
in policy making.METHODS: Two questionnaires were designed targeting both PM
involved in developing health policy (such as government ministers, officials and
senior public servants within national and/or local health services) and senior staff
with extensive experience working in a SAB. The questionnaire was sent to 25 PM
and to 29 SAB staff. Descriptive analysis was carried out. RESULTS: Nineteen PM (3
Belgium, 1 Czech Republic, 1 Lithuania, 2 the The Netherlands, 2 Poland, 1 Roma-
nia, 5 Spain, 3 Sweden and 1 UK) and 25 SAB staff (1 Belgium, 1 Czech Republic, 1
Italy,1 Lithuania, 4 the The Netherlands, 1 Poland, 3 Romania, 11 Spain, and 2 from
Sweden) responded the questionnaire. Factors seen as barriers for the relationship
between PM and SAB are the differences in timing, interest, and difficulties to
translate policy problems into research questions. The communication was seen
as informal. PM and SAB considered that usefulness of SA could be improved with
more clarity, brevity, simplicity and concise reporting. Transparency, indepen-
dency, existence of procedures to adequately deal with conflict of interest, rigor
and systematization of knowledge are factors ranked with highest value.
CONCLUSIONS: Proposals to improve the SA process are “organising regular high
level meetings” and “improve the trust between decisors and researchers”.
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